Get the Stockscreener App
20.94
0.00%
0.00
Dyne Therapeutics Inc stock is traded at $20.94, with a volume of 5.44M.
It is up +0.00% in the last 24 hours and up +15.37% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$20.94
Open:
$20.96
24h Volume:
5.44M
Relative Volume:
3.02
Market Cap:
$3.46B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-6.4908
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+5.76%
1M Performance:
+15.37%
6M Performance:
+4.49%
1Y Performance:
+108.36%
1-Day Range:
$20.42
$21.62
1-Week Range:
$20.11
$21.62
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
20.94 | 3.41B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
Enterprise value to EBIT forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Price to earnings forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
Price to earnings forward of Dyne Therapeutics Inc – BX:DYN - TradingView
Enterprise value to revenue forward of Dyne Therapeutics Inc – BX:DYN - TradingView
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
DYN Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - Moomoo
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
TD Cowen Initiates Dyne Therapeutics(DYN.US) With Buy Rating - Moomoo
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com Canada
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com
Dyne Therapeutics stock initiated at buy by TD Cowen on platform By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Form 144 Dyne Therapeutics For: 25 June By Investing.com - Investing.com Nigeria
Dyne Therapeutics Inc Actuals & Estimates (NASDAQ:DYN) - TradingView
How (DYN) Movements Inform Risk Allocation Models - Stock Traders Daily
Erick Lucera files Form 144 to sell DYN shares (DYN) - Stock Titan
DYN Forecast — Price Target — Prediction for 2027 - TradingView
Dyne Therapeutics director Kersten sells $5.46 million in shares By Investing.com - Investing.com South Africa
Dyne Therapeutics director Kersten sells $5.46 million in shares - Investing.com UK
Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
Form 144 Dyne Therapeutics For: 24 June By Investing.com - Investing.com South Africa
Dyne Therapeutics(DYN.US) Director Sells US$5.46 Million in Common Stock - Moomoo
Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing - marketscreener.com
Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan - Stock Titan
Dyne Therapeutics (DYN) Expands Term Loan Facility with Hercules Capital by $400M to Advance Clinical Pipeline - Insider Monkey
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Form 144 Dyne Therapeutics For: 23 June By Investing.com - Investing.com Australia
Dyne Therapeutics Names Barry Greene Independent Board Director - The Globe and Mail
Director at Dyne Therapeutics (DYN) awarded 57,463 stock options vesting over 3 years - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) director Barry Greene files initial Form 3 - Stock Titan
Dyne Therapeutics Appoints Barry Greene to Board of Directors - Sahm
Dyne Therapeutics (DYN) Is Up 12.1% After Expanding Debt Facility And Adding Veteran Biotech Director - Sahm
Dyne Therapeutics appoints Barry Greene to board of directors - Investing.com UK
Dyne Therapeutics appoints Barry Greene to board of directors By Investing.com - Investing.com South Africa
Dyne Therapeutics elects Barry E. Greene to Board as Class I director - TradingView
Barry Greene joins Dyne Therapeutics (DYN) board with new option grant - Stock Titan
Entity tied to Dyne (DYN) director sells 84K pre-planned shares - Stock Titan
Dyne Therapeutics, Inc. Announces Appointment of Barry Greene to Board of Directors - marketscreener.com
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 18, 2026 - marketscreener.com
Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Dyne Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Dyne Therapeutics Inc (DYN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dyne Therapeutics Inc (DYN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dyne Therapeutics Inc (DYN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):